The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.
A new additional drug in the fight against the opioid overdose crisis has slowly been making its way across the country and ...
This issue of the Mass Torts Update addresses the United Judicial Panel on Multidistrict Litigation ordering the ...
AtriCure, Inc. , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced ...
Veradigm's interim CEO Yin Ho has an audacious plan to reinvent what was formerly Allscripts with the $140 million ...
Deadly, addictive fentanyl has certainly earned the spotlight when it comes to overdose deaths — but carnage from stimulants ...
Jaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US market: San Francisco, California Thursday, April 18, 2024, 12:00 Hrs [IST] Jaguar He ...
The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter; Four upcoming milestones expected: data ...
Thursday's edition of Forbes Daily covers the crypto halving event, Taylor Swift's new album, MMA's place as top combat sport ...
Bennett Braun, MD, the psychiatrist who promoted "Satanic Panic" when he claimed that dozens of his patients had discovered ...
The Food and Drug Administration (FDA) has issued a public notification on S.W.A.G., advising consumers against purchasing ...